Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
OPXA volume drying up, 10% new stakeholder and good merck deal worth up to 225mln recently Starting position 2.14 on retrace from 5$ -------------------- 12 february Opexa Therapeutics: Sabby Management disclosed 9.58% passive stake in 13G filing out last night ----------------------- Febr 7th InPlay: Opexa Therapeutics prices offering of shares of its common stock and warrants to purchase common stock in a private registered offering of 1,083,334 units at $3.00 per unit ------------------------------------- Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna™ (imilecleucel-T) for Treatment of Multiple Sclerosis Merck Serono granted option for exclusive license from Opexa to develop and commercialize Tcelna (imilecleucel-T), an investigational T-cell therapy for patients suffering from multiple sclerosis (MS) THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA) today announced the execution of an agreement with Merck Serono, a division of Merck, Darmstadt, Germany, for the development and commercialization of Tcelna™ (imilecleucel-T), a potential first-in-class personalized T-cell therapy for patients suffering from multiple sclerosis (MS). Tcelna (imilecleucel-T) is being developed by Opexa and currently is in a Phase IIb clinical trial in patients with Secondary Progressive MS (SPMS). Potential payments to Opexa from the option and license agreement could total $225 million based upon the successful development and commercialization of Tcelna for MS. Tcelna (imilecleucel-T) is being developed as a personalized therapy specifically tailored to each patient’s individual disease profile and has been evaluated in Phase I and II clinical studies in MS that included SPMS patients. Tcelna (imilecleucel-T) has received Fast Track Designation from the United States Food and Drug Administration as a potential treatment for SPMS. Under the terms of the agreement, Opexa will receive an upfront payment of $5 million for granting an option to Merck Serono for the exclusive license of the Tcelna (imilecleucel-T) program for the treatment of MS. The option may be exercised prior to or upon completion of Opexa’s ongoing Phase IIb clinical trial in patients with SPMS. Upon exercising this licensing option, Merck Serono would pay an upfront license fee of either $25 million or $15 million (depending upon whether certain conditions are met), and in return receive worldwide development and commercial rights to Tcelna (imilecleucel-T) in MS, excluding Japan. After exercising the option Merck Serono would be wholly responsible for funding clinical development, subject to Opexa’s co-funding option, as well as regulatory and commercialization activities for the MS program. Additional financial considerations of the agreement include development and commercial milestone payments to Opexa of up to $195 million and a tiered royalty rate from the high single digits to the mid-teens based on net sales payable to Opexa. The potential payments to Opexa could, therefore, total $225 million excluding royalty payments. Under the agreement, Opexa will have an option right to co-fund development, under which the Company would participate in economic support for future clinical development of the program in exchange for additional royalty consideration. In addition to retaining all rights outside of MS as well as retaining the ability to commercialize Tcelna (imilecleucel-T) in Japan, Opexa also retains certain manufacturing rights related to the program. Further details of the transaction are included in a Form 8-K that was filed this morning by Opexa with the United States Securities and Exchange Commission. “Merck Serono is strongly committed to developing innovative drug candidates like Tcelna (imilecleucel-T), a potential first-in-class personalized cell therapy for patients with multiple sclerosis,” said Susan Herbert, Head of Global Business Development and Strategy at Merck Serono. “This agreement illustrates Merck Serono’s commitment to employ creative ways of accessing external innovation to develop potential next generation multiple sclerosis treatments, especially in secondary progressive multiple sclerosis, an area of high unmet need.” Neil K. Warma, President and Chief Executive Officer of Opexa, commented, “Opexa is pleased to partner with Merck Serono and given Merck Serono’s long-term strategic commitment to, and existing franchise position in the field of multiple sclerosis, we could not ask for a more experienced partner to carry Tcelna (imilecleucel-T) through development and hopefully to the market and to patients. We also are pleased to retain important rights through this transaction, such as certain manufacturing rights, commercialization rights to the Japanese market and a co-funding of development option, as well as rights for all indications outside of MS, all of which are intended to enhance Opexa shareholder value.”
voorbeurs al 50k verhandeld op 1,48.gebeurd niet vaak zo vroeg. misschien wat nieuws op komst? succes gr ber
Loos alarm. Vandaag bijgekocht ad. $ 1,39. Die $ 1,50 van de emissie zou een bodem kunnen leggen, ik zeg het voorzichtig, want bij GLPG dook de koers onlangs na een emissie tegen € 20 naar beneden richting € 15 nu.
9 Compelling Reasons To Buy Opexa Therapeutics Right Now Aug 15 2013, 12:44 | (1) Shares Just Above Cash Value Opexa just completed an $18 million capital raise, bolstering the company's balance sheet with a solid cash buffer that should be welcomed by investors. Combined with the existing cash on its balance sheet, Opexa is currently trading just barely above its net cash. Investors are effectively paying nothing for the business at current levels; a virtually free option on a potentially game-changing MS drug as well as other possible indications. (2) Elimination of Capital Raise Overhang A dilutive capital raise at a significant discount to market is a continual concern for investors in speculative small-cap biotech stocks. The only reason Opexa's capital raise appears to have been priced at a large discount is that its shares staged a massive run immediately prior to the funding. In actuality, shares were effectively priced at the market. Notably, Opexa did not issue warrants as part of this offering, thus minimizing the dilutive consequences to exiting shareholders. This is in stark contrast to many small-cap biotech financings, in which investors demand dilutive warrants in addition to discounted shares as an incentive to participate. Finally, as Merck Serono (MRK.DE) is wholly responsible for funding clinical development and regulatory and commercialization activities for the MS program (see below), Opexa has eliminated the overhang of a capital raise for existing shareholders for the foreseeable future. In fact, on this week's conference call, CFO Karthik Radhakrishnan announced that the company, with a monthly burn rate of $1.2 million/month,now has sufficient capital to take it to through the second half of 2014, well beyond what most comparable biotechs can claim. (3) Collaboration with Merck Serono Most speculative biotech companies are in a continual desperate search for a big-name partner to help support and finance their drug pipeline. Opexa has already secured such a relationship with the industry giant Merck Serono for its flagship drug Tcelna . Additional details of this significant collaboration can be found here. As noted above, Merck is responsible for funding the entirety of clinical and regulatory expenses, and Opexa is eligible for payments of up to $220 million. It is critical to note, as CEO Neil Warma emphasized in the quarterly conference call, Opexa has retained full rights to all other indications for Tcelna outside of MS. (4) Insider Purchase The CFO of Opexa, Karthik Radhakrishnan, just disclosed the purchase of 50,000 shares at $1.5, where the company's stock offering was priced. An executive's participation in the company's financing is looked upon favorably by the investment community as a sign of confidence in its future prospects. An outside investor can currently purchase shares on the open market at a discount to the CFO's shares, representing an even greater bargain. Additionally, it is worth noting that no insider sales have occurred at the company in almost 4 years. (5) Historically Favorable Risk-Reward Warren Buffet famously quipped, "Be Fearful When Others Are Greedy and Greedy When Others Are Fearful." Opexa shares are trading near all time lows, and are 75% off 52 week highs, despite a number of material developments that have markedly improved the prospects of the company. These include a strengthening of the company's cash position arising from royalty payments and capital raises, in addition to the Merck collaboration discussed above. Virtually all other equally (or even more) speculative biotech stocks trade with a market capitalization five to ten times higher than Opexa's, including those of Peregrine Pharamaceuticals (PPHM), Cell Therapeutics (CTIC), Geron Corporation (GERN), AVEO Pharma (AVEO), and XOMA Corporation (XOMA). Opexa shares present a compelling buy opportunity for the speculative investor at current levels. Currently, the market is assigning a near-zero probability of Tcelna's efficacy in the treatment of multiple sclerosis (MS). Given that MS is such a notoriously challenging disease to conquer, the first indication that Tcelna provides relief to MS patients will literally drive the shares 10x overnight. (6) Catalyst Driven Momentum Stock From a longer-term investment perspective, the success of Opexa's drug pipeline will ultimately determine how high the stock is valued. In the interim, a variety of other factors play a large part in where shares of Opexa trade. Opexa is the ultimate biotech story stock, attracting a wide array of speculative and momentum investors. What this means is that any whiff of positive news, or even vague rumors, will and have moved this stock dramatically. One look at the multi-year chart will verify this phenomenon. As a head trader at briefing.com, who recently took a stake in Opexa, describes it: "I've taken a Swing Long position in the name with plans to stash away in my spec portfolio. I view it as a biotech hype name that will be hyped again at some point b/c it has a story that can be sold. (1.37 -0.04) I'm looking at it as a situation where I'm willing to risk 50% to potentially make 200%. It's a total spec play, not an investment based on fundamentals. I may be in this for months/quarters, but it is a relatively small position for me." In all likelihood, shares of Opexa will enjoy a multitude substantial rallies well before Phase 3 clinical results are available, providing less patient investors with an opportunity to profit .
(7) Management Commentary Opexa just held its quarterly conference call to discuss financial results and provide a corporate update. The conference call and accompanying slides revealed a few gems that may be under the radar of the investment community. CEO Warma divulged that the safety profile of the enrolled patient population remains "superb." As noted above, the CFO specified that the company has enough cash to take it in until late 2014. Management also emphasized the possibilities that its drug platform potentially holds in treating diseases outside of the realm of MS. (8) Upcoming Analyst Coverage Similar to (6), this investment rationale focuses less on the science of Opexa than the underpinnings of Wall Street and how to profit from it as an investor. Aegis Capital led the underwriting of Opexa's recent secondary offering. Aegis is well-known on the Street for raising funds for a wide array of small-cap biotechs. Quite frequently, the research department of Aegis will subsequently initiate coverage of these biotechs. If history is any indication, I expect to see a very ambitious price target slapped on shares of Opexa in the near future. (9) Takeover Speculation Shares of Opexa recently staged a furious rally, surging from $1.26 to $3.7 in less than a day. As Seeking Alpha's Market Currents noted: The rumor mill is abuzz: Comments from Merck KGaA (MKGAF.PK) regarding a 2-3% market share loss for the MS treatment Rebif at the hands of Biogen's Tecfidera are fueling speculation that the German drug and materials company may heighten its focus on Tcelna, a treatment for Secondary Progressive MS being developed in conjunction with Opexa Therapeutics. Trading desks further speculated that Merck may be interested in buying Opexa outright, adding fuel to the fire and rocketing shares still higher. I wouldn't be surprised to see this chatter resurface, as it often does in the biotech world. In addition, Merck was apparently not the only big pharma interested in Opexa as their collaboration was being negotiated. CEO Neil Warma revealed that the company received interest "from a number of other pharmaceutical companies because there are few treatment options for patients with multiple sclerosis." The company ultimately decided to partner with Merck for its widely acknowledged leadership role in the fight against MS. Of course, any investment in a small-cap biotech is inherently speculative, and those involved need to be aware of the substantial risks involved with venturing into this realm of the stock market. However, I believe Opexa currently represents one of the most favorable risk-reward profiles in the speculative biotech sector for all of the reasons outlined above. Opexa shares have a history of breathtaking rallies that can be highly lucrative for investors who make timely purchases of shares at the right price. Now is that time. Source: 9 Compelling Reasons To Buy Opexa Therapeutics Right Now
Haal er weinig negatiefs uit.Maar zullen waarschijnlijk 2de deel van 2014 wel geld gaan ophalen.
Zeer weinig handel,al een uur geen stukje verhandeld. gisteren toch weinig negatiefs vermeld,afgelopen twee dagen viel er bij INO geld te verdienen.
Er is een storing gaande bij meerdere aandelen
Gisteren leek hij toch te vertrekken maar viel toch weer wat terug. kijken of hij vandaag een serieuze stap kan maken. gr ber
finance.yahoo.com/news/opexa-announce... voorbeurs in ieder geval positieve handel (weinig,maar toch)
Nu toch in de vijftigers beland met goed volume,ben benieuwd of hij vandaag daadwerkelijk een stap omhoog kan maken. Gr. Ber
Hij zet lekker door,goed volume
us.rd.yahoo.com/finance/external/pssa... Hier zitten toch positieve zaken tussen. Vandaag rond 21:00 uur conference call,wie weet wat het brengt. Laatste dagen goed volume met stijging,vandaag verder? Gr ber
pre markt is positief gr ber
Hij gaat los. Bijgekocht op 1,64.
Maximaal! schreef op 10 september 2013 11:02 :
us.rd.yahoo.com/finance/external/pssa... Hier zitten toch positieve zaken tussen.
Vandaag rond 21:00 uur conference call,wie weet wat het brengt.
Laatste dagen goed volume met stijging,vandaag verder?
Gr ber
Zie 21 augustus, 18.32.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
874,79
+0,96%
EUR/USD
1,0705
+0,50%
FTSE 100
8.044,81
+0,26%
Germany40^
18.148,30
+1,61%
Gold spot
2.328,26
+0,04%
NY-Nasdaq Composite
15.451,31
+1,11%
Stijgers
Dalers